Yan Dong’s research while affiliated with Kunming Medical University and other places

Human papillomavirus (HPV) has been confirmed as the causative agent for cervical cancer. In this study, a total of 301 880 women were recruited from four different regions of Western China, with 301 880 exfoliated cervical cell samples collected from women for DNA isolation and purification. The HPV genotype was tested by polymerase chain reaction. The overall HPV prevalence rate, high-risk (HR) HPV infection rate, low-risk (LR) HPV infection rate and mixed HPV infection rate was 18.24%, 79.14%, 12.56% and 8.30%, respectively. The four most common HR HPV subtypes were HPV-52, 16, 58 and 53, which accounted for 20.49%, 19.93%, 14.54% and 10.01%, respectively. In LR HPV genotype, HPV-6 ranked the highest (28.17%), followed by HPV-81 (9.09%) and HPV-11 (3.78%). HPV genotype subgroup analysis also showed that single-type infection was the most common (77.26%) among HPV-positive individuals. Among multi-infection genotypes, double infection was the most common with frequencies of 76.04%. The overall prevalence of HPV is high in Western China, whose distribution demonstrates different patterns across different ages and regions. Viral genotypes HPV 53, 6 were frequently detected in this population, which is worth of significant clinical attention.

In this study, a total of 301,880 woman were recruited from 4 different regions of China. The overall prevalence of HPV was 18.01 %. The high-risk HPV infection rate was 79.14%, the low-risk HPV infection rate was 12.56 %, and the mixed HPV infection rate was 8.30%. The most common 4 HR HPV subtypes were HPV-52, 16, 58 and 53, which accounted for 20.49 %, 19.93 %, 14.54 % and 10.01 %. In LR HPV genotype, HPV-6 ranked the highest (28.17 %), followed by HPV-81 (9.09 %) and HPV-11 (3.78 %). HPV genotype subgroup analysis also showed that single-type infections had the highest prevalence rate (77.26 %) among HPV positive individuals. Among muti-infection genotype, double infection was the most common with frequencies of 76.04 %. This large report showed that the overall prevalence of HPV was high in China, whose distribution exhibits different patterns across different particular age and regions. Viral genotypes HPV 53, 6 were frequently detected in this population, which is worth of significant clinical attention.

With the increasing incidence of papillary thyroid cancer (PTC), it is important to risk-stratify patients who may have a more aggressive tumor biology. The present study aimed to evaluate the risk factors for lymph node metastasis (LNM) in patients with PTC, which may provide a significant reference for clinical diagnosis and treatment. In total, 1,045 patients with PTC [313 with PT microcarcinoma (PTMC) and 732 with non-PTMC] between August 2016 and August 2019 were investigated. The B-type Raf kinase (BRAF) V600E mutation was tested in all samples. The clinical data (sex, age, tumor location, sample type and pathological features) were retrospectively analyzed. Logistic regression analysis was performed to evaluate independent risk factors for LNM. A total of 181/313 (57.8%) PTMC cases and 145/732 (19.8%) non-PTMC cases had a BRAF V600E mutation. In the PTMC cases, significant differences in sex and sample type were identified (BRAF V600E mutation vs. wild-type). In the non-PTMC cases, significant differences in sex and age were identified (BRAF V600E mutation vs. wild-type). Female sex and tumor diameter ≤1 cm were significant independent predictors of LNM in PTC. In PTMC, female sex was a significant independent predictor of LNM. A bilateral tumor was an independent protective factor for LNM in PTC, PTMC and non-PTMC. The BRAF V600E mutation rate of ultrasound-guided fine-needle aspiration cytology was higher compared with FFPE in PTMC (P=0.018). In contrast to previous studies, the results of the present study suggested that being female and having a tumor of diameter ≤1 cm were risk factors for LNM, and that the BRAF wild-type of PTMC may be more aggressive than other types. Notably, the position of the tumor in the bilateral thyroid was also an independent protective factor for LNM. Therefore, ultrasound-guided fine-needle aspiration should be recommended for gene analysis (BRAF V600E) in PTMC. In addition, clinicians should consider an individualized treatment according to gene mutations, sex, age, tumor size and the location of the tumor, in order to achieve an improved therapeutic efficacy.

Background: With the increasing incidences of papillary thyroid cancer(PTC), it is important to risk-stratify patients who may have more aggressive tumor biology. This study aimed to evaluate the risk factors for lymph node metastasis with PTC in Southwest China Patients which may provide a substantial reference for clinical diagnosis and treatment. Methods: 1045 PTCs (313 PTMC and 732 non-PTMC) between August 2016 and August 2019 were examined totally (including one Tibetan). BRAF V600E mutation was tested in all samples. The clinical data (gender, age, tumor location, sample source and pathological features) were retrospectively analyzed. Logistic regression analysis was performed to evaluate independent risk factors for LNM. Results: 181 out of 313 PTMC cases (57.8%), 145 out of 732 non-PTMC cases (19.8%) had BRAF V600E mutation, the Tibetan had a double mutation of BRAF L597Q and V600E in two separate lesions. In PTMC, significant difference in gender and sample source was found (BRAF V600E mutation vs. wild-type). In non-PTMC, significant difference in gender was found (BRAF V600E mutation vs. wild-type). The female (OR=1.952; 95% CI= 1.373-2.774; P= 0.00), age (31-59 years) and diameter of tumor ≤1cm (OR=3.273; 95% CI= 2.417-4.432; P=0.000) were significant independent predictors of LNM in all PTCs. In PTMC, the female (OR= 3.002; 95% CI= 1.654-5.446; P= 0.00) was a significant independent predictor of LNM. The tumor in left and right lobes simultaneously was an independent protective factor of LNM in each group (PTCs: OR=0.287; PTMC: OR=0.170; non-PTMC: OR=0.441, respectively). The BRAF V600E mutation rate of US-FNAC was much higher than FFPE in PTMC (P=0.018). Conclusions: Unlike previous research, our findings suggested that the female patients and diameter of tumor ≤1cm were risk factors for LNM and the BRAF V600E wild-type of PTMC might be more aggressive than others. Interestingly, the position of tumor in bilateral thyroid simultaneously was an independent protective factor for LNM. The US-FNA should be recommended for gene analysis (BRAF V600E) in PTMC. The BRAF L597Q mutation may be an independent aggressive factor in the Chinese Tibetan population. Hence, clinicians should consider an individualized treatment according to gene mutation, gender, age, tumor size and location of tumor in order to achieve a better therapeutic efficacy.

Thousands of long non-coding RNAs (lncRNAs) have been discovered in human genomes by gene chip, next-generation sequencing, and/or other methods in recent years, which represent a significant subset of the universal genes involved in a wide range of biological functions. An abnormal expression of lncRNAs is associated with the growth, invasion, and metastasis of various types of human cancers, including hepatocellular carcinoma (HCC), which is an aggressive, highly malignant, and invasive tumor, and a poor prognosis in China. With a more in-depth understanding of lncRNA research for HCC and the emergence of new molecular-targeted therapies, the diagnosis, treatment, and prognosis of HCC will be considerably improved. Therefore, this review is expected to provide recommendations and directions for future lncRNA research for HCC.